Craig Davies-Cutting

Craig Davies-Cutting has extensive experience in the pharmaceutical industry, specifically in research and development.

Starting in 2003, they worked at Catalent, where they held various roles over the years. Craig served as the Director of Inhalation Formulation Development from September 2004 to June 2007, overseeing the development of inhaled products such as MDIs, DPIs, Nebules, and Nasal products.

In June 2007, they took on an expanded role as the Director of Research and Development, leading a team of over 70 staff members. In this position, they not only supervised formulation aspects but also managed all elements of inhaled product development programs, as well as sterile product development and an analytical R&D team.

From October 2010 to March 2019, Craig served as the Director of Inhaled Products & Technologies at Catalent, focusing on the development of inhaled products.

In March 2019, they took on the role of Director of Product Development, overseeing the development of various products. Craig remained in this position until October 2022.

Currently, Craig Davies-Cutting is the Vice President of Research & Development at Nob Hill Therapeutics, a position they have held since October 2022.

Craig Davies-Cutting has a Doctor of Philosophy - PhD degree in Physical Chemistry from the University of Bristol. During their time there, they focused on studying "The Effects of Suspension Stability on Metered Dose Inhaler Performance". Prior to their PhD, they earned a Master of Science (MSc) degree in Analytical Chemistry from Birkbeck, University of London. Their undergraduate education includes a Bachelor of Science (BSc) degree in Applied Chemistry from Nottingham Trent University.